View Future GrowthRetractable Technologies 과거 순이익 실적과거 기준 점검 0/6Retractable Technologies 의 수입은 연평균 -70.3%의 비율로 감소해 온 반면, Medical Equipment 산업은 연평균 13.6%의 비율로 증가했습니다. 매출은 연평균 38%의 비율로 감소해 왔습니다.핵심 정보-70.33%순이익 성장률-69.66%주당순이익(EPS) 성장률Medical Equipment 산업 성장률8.90%매출 성장률-37.98%자기자본이익률-8.97%순이익률-17.55%최근 순이익 업데이트31 Mar 2026최근 과거 실적 업데이트Reported Earnings • May 18First quarter 2026 earnings released: US$0.14 loss per share (vs US$0.35 loss in 1Q 2025)First quarter 2026 results: US$0.14 loss per share (improved from US$0.35 loss in 1Q 2025). Revenue: US$7.18m (down 14% from 1Q 2025). Net loss: US$4.28m (loss narrowed 59% from 1Q 2025). Over the last 3 years on average, earnings per share has fallen by 20% per year whereas the company’s share price has fallen by 19% per year.Reported Earnings • Mar 30Full year 2025 earnings released: US$0.43 loss per share (vs US$0.41 loss in FY 2024)Full year 2025 results: US$0.43 loss per share (further deteriorated from US$0.41 loss in FY 2024). Revenue: US$38.3m (up 16% from FY 2024). Net loss: US$12.8m (loss widened 5.6% from FY 2024). Over the last 3 years on average, earnings per share has fallen by 45% per year but the company’s share price has only fallen by 27% per year, which means it has not declined as severely as earnings.Reported Earnings • Nov 16Third quarter 2025 earnings released: EPS: US$0.01 (vs US$0.066 loss in 3Q 2024)Third quarter 2025 results: EPS: US$0.01 (up from US$0.066 loss in 3Q 2024). Revenue: US$10.1m (down 2.5% from 3Q 2024). Net income: US$313.4k (up US$2.29m from 3Q 2024). Profit margin: 3.1% (up from net loss in 3Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 48 percentage points per year, which is a significant difference in performance.Reported Earnings • Mar 30Full year 2024 earnings released: US$0.41 loss per share (vs US$0.24 loss in FY 2023)Full year 2024 results: US$0.41 loss per share (further deteriorated from US$0.24 loss in FY 2023). Revenue: US$33.0m (down 24% from FY 2023). Net loss: US$12.1m (loss widened 67% from FY 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 76 percentage points per year, which is a significant difference in performance.Reported Earnings • Nov 17Third quarter 2024 earnings released: US$0.066 loss per share (vs US$0.14 loss in 3Q 2023)Third quarter 2024 results: US$0.066 loss per share (improved from US$0.14 loss in 3Q 2023). Revenue: US$10.3m (flat on 3Q 2023). Net loss: US$1.98m (loss narrowed 52% from 3Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 60 percentage points per year, which is a significant difference in performance.Reported Earnings • Aug 16Second quarter 2024 earnings released: US$0.47 loss per share (vs US$0.13 loss in 2Q 2023)Second quarter 2024 results: US$0.47 loss per share (further deteriorated from US$0.13 loss in 2Q 2023). Revenue: US$6.03m (down 24% from 2Q 2023). Net loss: US$14.2m (loss widened 262% from 2Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 55 percentage points per year, which is a significant difference in performance.모든 업데이트 보기Recent updatesReported Earnings • May 18First quarter 2026 earnings released: US$0.14 loss per share (vs US$0.35 loss in 1Q 2025)First quarter 2026 results: US$0.14 loss per share (improved from US$0.35 loss in 1Q 2025). Revenue: US$7.18m (down 14% from 1Q 2025). Net loss: US$4.28m (loss narrowed 59% from 1Q 2025). Over the last 3 years on average, earnings per share has fallen by 20% per year whereas the company’s share price has fallen by 19% per year.공시 • Mar 30Retractable Technologies, Inc., Annual General Meeting, May 08, 2026Retractable Technologies, Inc., Annual General Meeting, May 08, 2026.Reported Earnings • Mar 30Full year 2025 earnings released: US$0.43 loss per share (vs US$0.41 loss in FY 2024)Full year 2025 results: US$0.43 loss per share (further deteriorated from US$0.41 loss in FY 2024). Revenue: US$38.3m (up 16% from FY 2024). Net loss: US$12.8m (loss widened 5.6% from FY 2024). Over the last 3 years on average, earnings per share has fallen by 45% per year but the company’s share price has only fallen by 27% per year, which means it has not declined as severely as earnings.Reported Earnings • Nov 16Third quarter 2025 earnings released: EPS: US$0.01 (vs US$0.066 loss in 3Q 2024)Third quarter 2025 results: EPS: US$0.01 (up from US$0.066 loss in 3Q 2024). Revenue: US$10.1m (down 2.5% from 3Q 2024). Net income: US$313.4k (up US$2.29m from 3Q 2024). Profit margin: 3.1% (up from net loss in 3Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 48 percentage points per year, which is a significant difference in performance.Board Change • Oct 23Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 5 highly experienced directors. VP, CFO, Principal Accounting Officer,Treasurer & Director John Fort was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.공시 • Jul 24Retractable Technologies, Inc. Announces Reduction in Manufacturing WorkforceRetractable Technologies, Inc. reported that it has reduced its workforce by approximately 12.4%. The reduction is expected to save an estimated $1.6 million in annual wages and benefits, or approximately 8.6% of total estimated workforce costs. The expected savings is offset by one-time separation payments of approximately $56,000 to the affected workers. The reduction targets the Company's manufacturing and manufacturing support positions as the Company continues to balance its domestic manufacturing presence against its reliance on imported products and associated tariffs from its Chinese contract manufacturers. While contract manufacturers in China have historically produced most of the products the Company sells, the material financial impact of tariffs on Chinese imports has caused the Company to ramp-up its domestic production activities, while working to minimize the financial impact of the change. To the extent possible, the Company will continue to import only those products which it cannot make domestically and rely on its Little Elm facility to produce the remainder of its products. The Company is unable to predict future U.S. trade policy, or the potential impact it may have on the Company's ability to import products from China or other countries.Board Change • Jul 10Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 4 highly experienced directors. VP, CFO, Principal Accounting Officer,Treasurer & Director John Fort was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.공시 • Apr 11Retractable Technologies, Inc. Announces Reduction in WorkforceRetractable Technologies, Inc. reported that it has reduced its workforce by approximately 7%. The reduction is expected to save an estimated $1.6 million in annual wages and benefits, or approximately 7.8% of total estimated workforce costs. The expected savings is offset by one-time separation payments of approximately $300,000 to the affected workers. Approximately 72% of the targeted payroll reduction affects general and administrative functions, with the remainder coming from manufacturing or manufacturing support positions. The move comes as the Company continues to allocate more of its resources to increase its U.S. manufacturing capabilities and reduce reliance on products produced in China. While contract manufacturers in China have historically produced most of the products the Company sells, the material financial impact of tariffs on imports from China eliminates the Company’s ability to continue the practice. As a result, the Company will work to minimize its exposure to the tariffs and strategically import only those products which it cannot make domestically and rely on its Little Elm facility to produce the majority of its products. The Company is unable to predict future U.S. trade policy, or the potential impact it may have on the Company’s ability to import products from China or other countries.공시 • Mar 31Retractable Technologies, Inc., Annual General Meeting, May 09, 2025Retractable Technologies, Inc., Annual General Meeting, May 09, 2025.Reported Earnings • Mar 30Full year 2024 earnings released: US$0.41 loss per share (vs US$0.24 loss in FY 2023)Full year 2024 results: US$0.41 loss per share (further deteriorated from US$0.24 loss in FY 2023). Revenue: US$33.0m (down 24% from FY 2023). Net loss: US$12.1m (loss widened 67% from FY 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 76 percentage points per year, which is a significant difference in performance.Reported Earnings • Nov 17Third quarter 2024 earnings released: US$0.066 loss per share (vs US$0.14 loss in 3Q 2023)Third quarter 2024 results: US$0.066 loss per share (improved from US$0.14 loss in 3Q 2023). Revenue: US$10.3m (flat on 3Q 2023). Net loss: US$1.98m (loss narrowed 52% from 3Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 60 percentage points per year, which is a significant difference in performance.Reported Earnings • Aug 16Second quarter 2024 earnings released: US$0.47 loss per share (vs US$0.13 loss in 2Q 2023)Second quarter 2024 results: US$0.47 loss per share (further deteriorated from US$0.13 loss in 2Q 2023). Revenue: US$6.03m (down 24% from 2Q 2023). Net loss: US$14.2m (loss widened 262% from 2Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 55 percentage points per year, which is a significant difference in performance.Reported Earnings • May 17First quarter 2024 earnings released: EPS: US$0.012 (vs US$0.031 in 1Q 2023)First quarter 2024 results: EPS: US$0.012 (down from US$0.031 in 1Q 2023). Revenue: US$7.60m (down 31% from 1Q 2023). Net income: US$371.8k (down 60% from 1Q 2023). Profit margin: 4.9% (down from 8.5% in 1Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 43 percentage points per year, which is a significant difference in performance.Reported Earnings • Apr 01Full year 2023 earnings released: US$0.24 loss per share (vs US$0.15 profit in FY 2022)Full year 2023 results: US$0.24 loss per share (down from US$0.15 profit in FY 2022). Revenue: US$43.6m (down 54% from FY 2022). Net loss: US$7.24m (down 250% from profit in FY 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 23 percentage points per year, which is a significant difference in performance.공시 • Mar 30Retractable Technologies, Inc., Annual General Meeting, May 10, 2024Retractable Technologies, Inc., Annual General Meeting, May 10, 2024, at 10:00 Central Standard Time. Agenda: To vote on the election of three Class 2 Directors; and to consider other matters.Reported Earnings • Nov 17Third quarter 2023 earnings released: US$0.13 loss per share (vs US$0.16 profit in 3Q 2022)Third quarter 2023 results: US$0.13 loss per share (down from US$0.16 profit in 3Q 2022). Revenue: US$10.3m (down 55% from 3Q 2022). Net loss: US$4.00m (down 175% from profit in 3Q 2022). Over the last 3 years on average, earnings per share has fallen by 54% per year whereas the company’s share price has fallen by 55% per year.Reported Earnings • Aug 15Second quarter 2023 earnings released: US$0.13 loss per share (vs US$0.11 loss in 2Q 2022)Second quarter 2023 results: US$0.13 loss per share (further deteriorated from US$0.11 loss in 2Q 2022). Revenue: US$7.97m (down 44% from 2Q 2022). Net loss: US$3.93m (loss widened 6.1% from 2Q 2022). Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has fallen by 47% per year, which means it is performing significantly worse than earnings.Reported Earnings • May 17First quarter 2023 earnings released: EPS: US$0.031 (vs US$0.23 in 1Q 2022)First quarter 2023 results: EPS: US$0.031 (down from US$0.23 in 1Q 2022). Revenue: US$11.0m (down 75% from 1Q 2022). Net income: US$932.9k (down 88% from 1Q 2022). Profit margin: 8.5% (down from 17% in 1Q 2022). Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 37% per year, which means it is significantly lagging earnings.Reported Earnings • Mar 31Full year 2022 earnings released: EPS: US$0.15 (vs US$1.65 in FY 2021)Full year 2022 results: EPS: US$0.15 (down from US$1.65 in FY 2021). Revenue: US$94.8m (down 50% from FY 2021). Net income: US$4.85m (down 91% from FY 2021). Profit margin: 5.1% (down from 30% in FY 2021). Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has only increased by 12% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • Dec 01Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to US$1.97, the stock trades at a trailing P/E ratio of 2.2x. Average trailing P/E is 33x in the Medical Equipment industry in the US. Total returns to shareholders of 38% over the past three years.Reported Earnings • Nov 17Third quarter 2022 earnings released: EPS: US$0.16 (vs US$0.19 in 3Q 2021)Third quarter 2022 results: EPS: US$0.16 (down from US$0.19 in 3Q 2021). Revenue: US$23.1m (down 37% from 3Q 2021). Net income: US$5.33m (down 18% from 3Q 2021). Profit margin: 23% (up from 18% in 3Q 2021). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 57% per year but the company’s share price has only increased by 20% per year, which means it is significantly lagging earnings growth.Board Change • Nov 17Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 4 highly experienced directors. VP, CFO, Principal Accounting Officer,Treasurer & Director John Fort was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Valuation Update With 7 Day Price Move • Nov 10Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to US$2.05, the stock trades at a trailing P/E ratio of 2.2x. Average trailing P/E is 32x in the Medical Equipment industry in the US. Total returns to shareholders of 55% over the past three years.Valuation Update With 7 Day Price Move • Oct 19Investor sentiment improved over the past weekAfter last week's 18% share price gain to US$2.28, the stock trades at a trailing P/E ratio of 2.4x. Average trailing P/E is 32x in the Medical Equipment industry in the US. Total returns to shareholders of 81% over the past three years.Valuation Update With 7 Day Price Move • Sep 19Investor sentiment deteriorated over the past weekAfter last week's 18% share price decline to US$2.01, the stock trades at a trailing P/E ratio of 2.1x. Average trailing P/E is 33x in the Medical Equipment industry in the US. Total returns to shareholders of 99% over the past three years.Board Change • Sep 06Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 4 highly experienced directors. VP, CFO, Principal Accounting Officer,Treasurer & Director John Fort was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.공시 • Jun 26+ 1 more updateRetractable Technologies, Inc.(NYSEAM:RVP) dropped from Russell 2000 Dynamic IndexRetractable Technologies, Inc.(NYSEAM:RVP) dropped from Russell 2000 Dynamic Index공시 • Jun 07Retractable Technologies, Inc. Reports Reduction in WorkforceRetractable Technologies, Inc. reported that it has reduced its workforce by approximately 16% as a result of the substantial completion of its facility expansion efforts and the completion of U.S. government orders to provide its products for COVID-19 vaccination efforts. The staff reduction primarily affects its production, operations and logistics departments. The reduction will result in an overall annualized savings of approximately $2.1 million dollars, or 13% in annual payroll expense, and separation costs are expected to be approximately $200 thousand. The company expects that it will be able to maintain its current level of domestic production after the headcount reduction, and have significantly enhanced domestic production capacity upon completion of the expansion efforts.Board Change • Jun 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 4 highly experienced directors. VP, CFO, Principal Accounting Officer,Treasurer & Director John Fort was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Valuation Update With 7 Day Price Move • May 31Investor sentiment improved over the past weekAfter last week's 19% share price gain to US$4.63, the stock trades at a trailing P/E ratio of 3.4x. Average trailing P/E is 36x in the Medical Equipment industry in the US. Total returns to shareholders of 573% over the past three years.Reported Earnings • May 17First quarter 2022 earnings: EPS and revenues miss analyst expectationsFirst quarter 2022 results: EPS: US$0.23 (down from US$0.53 in 1Q 2021). Revenue: US$44.7m (down 11% from 1Q 2021). Net income: US$7.56m (down 58% from 1Q 2021). Profit margin: 17% (down from 36% in 1Q 2021). The decrease in margin was primarily driven by higher expenses. Revenue missed analyst estimates by 13%. Earnings per share (EPS) also missed analyst estimates by 47%. Over the last 3 years on average, earnings per share has increased by 94% per year but the company’s share price has only increased by 77% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • May 11Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to US$3.63, the stock trades at a trailing P/E ratio of 2.2x. Average trailing P/E is 33x in the Medical Equipment industry in the US. Total returns to shareholders of 438% over the past three years.Board Change • May 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 4 highly experienced directors. VP, CFO, Principal Accounting Officer,Treasurer & Director John Fort was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Valuation Update With 7 Day Price Move • Apr 22Investor sentiment deteriorated over the past weekAfter last week's 19% share price decline to US$3.64, the stock trades at a trailing P/E ratio of 2.2x. Average trailing P/E is 38x in the Medical Equipment industry in the US. Total returns to shareholders of 406% over the past three years.Reported Earnings • Apr 02Full year 2021 earnings: EPS and revenues miss analyst expectationsFull year 2021 results: EPS: US$1.65 (up from US$0.80 in FY 2020). Revenue: US$188.4m (up 130% from FY 2020). Net income: US$55.8m (up 110% from FY 2020). Profit margin: 30% (down from 33% in FY 2020). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 13%. Earnings per share (EPS) also missed analyst estimates by 47%. Over the last 3 years on average, earnings per share has increased by 109% per year but the company’s share price has only increased by 88% per year, which means it is significantly lagging earnings growth.공시 • Apr 01Retractable Technologies, Inc., Annual General Meeting, May 10, 2022Retractable Technologies, Inc., Annual General Meeting, May 10, 2022, at 10:00 Central Standard Time. Agenda: To consider the election of Three Class 2 Directors; and to consider an advisory vote to approve executive compensation.Reported Earnings • Nov 17Third quarter 2021 earnings released: EPS US$0.19 (vs US$0.33 in 3Q 2020)The company reported a mediocre third quarter result with weaker earnings and profit margins, although revenues improved. Third quarter 2021 results: Revenue: US$36.4m (up 34% from 3Q 2020). Net income: US$6.46m (down 41% from 3Q 2020). Profit margin: 18% (down from 41% in 3Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 120% per year but the company’s share price has increased by 134% per year, which means it is tracking significantly ahead of earnings growth.Valuation Update With 7 Day Price Move • Oct 05Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to US$10.03, the stock trades at a trailing P/E ratio of 6.6x. Average trailing P/E is 48x in the Medical Equipment industry in the US. Total returns to shareholders of 1,290% over the past three years.Reported Earnings • Aug 18Second quarter 2021 earnings released: EPS US$0.31 (vs US$0.11 in 2Q 2020)The company reported a solid second quarter result with improved earnings and revenues, although profit margins were weaker. Second quarter 2021 results: Revenue: US$42.5m (up 267% from 2Q 2020). Net income: US$10.6m (up 195% from 2Q 2020). Profit margin: 25% (down from 31% in 2Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 132% per year but the company’s share price has increased by 148% per year, which means it is tracking significantly ahead of earnings growth.공시 • Jun 28+ 2 more updatesRetractable Technologies, Inc.(NYSEAM:RVP) dropped from Russell 3000E Value IndexRetractable Technologies, Inc.(NYSEAM:RVP) dropped from Russell 3000E Value IndexValuation Update With 7 Day Price Move • Jun 09Investor sentiment improved over the past weekAfter last week's 19% share price gain to US$12.02, the stock trades at a trailing P/E ratio of 9.1x. Average trailing P/E is 56x in the Medical Equipment industry in the US. Total returns to shareholders of 1,384% over the past three years.공시 • Jun 08Retractable Technologies, Inc. (NYSEAM:RVP) announces an Equity Buyback for $10 million worth of its shares.Retractable Technologies, Inc. (NYSEAM:RVP) announces a share repurchase program. Under the program, the company will repurchase up to $10 million worth of common stock. The program is valid until June 18, 2022.Reported Earnings • May 19First quarter 2021 earnings released: EPS US$0.53 (vs US$0.005 in 1Q 2020)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: US$50.1m (up 347% from 1Q 2020). Net income: US$17.9m (up US$17.7m from 1Q 2020). Profit margin: 36% (up from 1.3% in 1Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 138% per year but the company’s share price has only increased by 120% per year, which means it is significantly lagging earnings growth.Recent Insider Transactions • Apr 24Independent Director recently sold US$50k worth of stockOn the 22nd of April, Walter Bigby sold around 5k shares on-market at roughly US$10.02 per share. In the last 3 months, they made an even bigger sale worth US$186k. Insiders have been net sellers, collectively disposing of US$5.1m more than they bought in the last 12 months.Valuation Update With 7 Day Price Move • Apr 08Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to US$10.59, the stock trades at a trailing P/E ratio of 13.2x. Average trailing P/E is 50x in the Medical Equipment industry in the US. Total returns to shareholders of 1,090% over the past three years.Reported Earnings • Apr 03Full year 2020 earnings released: EPS US$0.80 (vs US$0.075 in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: US$81.9m (up 96% from FY 2019). Net income: US$26.6m (up US$24.2m from FY 2019). Profit margin: 33% (up from 5.9% in FY 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 136% per year but the company’s share price has increased by 142% per year, which means it is tracking significantly ahead of earnings growth.분석 기사 • Mar 16Is Retractable Technologies (NYSEMKT:RVP) Using Too Much Debt?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Valuation Update With 7 Day Price Move • Mar 13Investor sentiment improved over the past weekAfter last week's 15% share price gain to US$13.65, the stock is trading at a trailing P/E ratio of 27.3x, up from the previous P/E ratio of 23.7x. This compares to an average P/E of 50x in the Medical Equipment industry in the US. Total returns to shareholders over the past three years are 1,275%.분석 기사 • Feb 26Do Insiders Own Lots Of Shares In Retractable Technologies, Inc. (NYSEMKT:RVP)?If you want to know who really controls Retractable Technologies, Inc. ( NYSEMKT:RVP ), then you'll have to look at the...Valuation Update With 7 Day Price Move • Feb 24Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to US$16.07, the stock is trading at a trailing P/E ratio of 32.2x, down from the previous P/E ratio of 38.2x. This compares to an average P/E of 56x in the Medical Equipment industry in the US. Total returns to shareholders over the past three years are 1,637%.Recent Insider Transactions Derivative • Feb 21Vice President of Sales Development notifies of intention to sell stockRussell Kuhlman intends to sell 13k shares in the next 90 days after lodging an Intent To Sell Form on the 19th of February. If the sale is conducted around the recent share price of US$17.04, it would amount to US$223k. Since March 2020, Russell's direct individual holding has decreased from 46.00k shares to 13.10k. Company insiders have collectively sold US$5.0m more than they bought, via options and on-market transactions in the last 12 months.공시 • Feb 18Retractable Technologies, Inc. Wins Firm Fixed Price and Cost Reimbursement Contract and Purchase OrderRetractable Technologies, Inc. announced that on February 12, 2021, it was awarded a firm fixed price and cost reimbursement contract and purchase order by the Department of Health and Human Services to supply low dead space safety syringes. The base price for the contract and purchase order is $54,217,800 for the five-month base period of performance (February 15, 2021 to July 14, 2021). Such price includes both the fixed price for the products as well as cost reimbursement for freight. The terms of the contract allow for extensions at the option of the U.S. government for up to seven additional one-month periods. If all option periods are exercised, the value of the contract could increase by an additional $92,772,680, including the price of the products and freight reimbursement. For each period, the freight cost is estimated at approximately 25% of the overall price.분석 기사 • Feb 08Retractable Technologies (NYSEMKT:RVP) Knows How To Allocate Capital EffectivelyTo find a multi-bagger stock, what are the underlying trends we should look for in a business? Firstly, we'll want to...Recent Insider Transactions • Feb 05Independent Director recently sold US$186k worth of stockOn the 2nd of February, Walter Bigby sold around 10k shares on-market at roughly US$18.55 per share. In the last 3 months, there was an even bigger sale from another insider worth US$3.0m. Insiders have been net sellers, collectively disposing of US$5.0m more than they bought in the last 12 months.Valuation Update With 7 Day Price Move • Jan 29Investor sentiment improved over the past weekAfter last week's 29% share price gain to US$16.17, the stock is trading at a trailing P/E ratio of 32.4x, up from the previous P/E ratio of 25.2x. This compares to an average P/E of 53x in the Medical Equipment industry in the US. Total returns to shareholders over the past three years are 2,087%.Is New 90 Day High Low • Jan 27New 90-day high: US$15.69The company is up 116% from its price of US$7.27 on 28 October 2020. The American market is up 17% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 9.0% over the same period.Recent Insider Transactions • Jan 22Founder recently sold US$3.0m worth of stockOn the 14th of January, Thomas Shaw sold around 210k shares on-market at roughly US$14.24 per share. This was the largest sale by an insider in the last 3 months. This was Thomas' only on-market trade for the last 12 months.Valuation Update With 7 Day Price Move • Jan 20Investor sentiment improved over the past weekAfter last week's 22% share price gain to US$13.57, the stock is trading at a trailing P/E ratio of 27.2x, up from the previous P/E ratio of 22.3x. This compares to an average P/E of 54x in the Medical Equipment industry in the US. Total returns to shareholders over the past three years are 1,798%.분석 기사 • Jan 12Here's Why I Think Retractable Technologies (NYSEMKT:RVP) Might Deserve Your Attention TodayFor beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...분석 기사 • Dec 28Here's Why We Don't Think Retractable Technologies's (NYSEMKT:RVP) Statutory Earnings Reflect Its Underlying Earnings PotentialStatistically speaking, it is less risky to invest in profitable companies than in unprofitable ones. Having said that...Valuation Update With 7 Day Price Move • Dec 23Investor sentiment deteriorated over the past weekAfter last week's 23% share price decline to US$11.64, the stock is trading at a trailing P/E ratio of 23.3x, down from the previous P/E ratio of 30.1x. This compares to an average P/E of 51x in the Medical Equipment industry in the US. Total returns to shareholders over the past three years are 1,696%.Is New 90 Day High Low • Dec 16New 90-day high: US$15.00The company is up 147% from its price of US$6.08 on 16 September 2020. The American market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 7.0% over the same period.Valuation Update With 7 Day Price Move • Dec 15Investor sentiment improved over the past weekAfter last week's 31% share price gain to US$12.77, the stock is trading at a trailing P/E ratio of 25.6x, up from the previous P/E ratio of 19.5x. This compares to an average P/E of 49x in the Medical Equipment industry in the US. Total returns to shareholders over the past three years are 1,751%.분석 기사 • Dec 14Does Retractable Technologies (NYSEMKT:RVP) Have A Healthy Balance Sheet?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Valuation Update With 7 Day Price Move • Dec 11Investor sentiment improved over the past weekAfter last week's 21% share price gain to US$12.09, the stock is trading at a trailing P/E ratio of 24.2x, up from the previous P/E ratio of 20x. This compares to an average P/E of 50x in the Medical Equipment industry in the US. Total returns to shareholders over the past three years are 1,540%.Valuation Update With 7 Day Price Move • Dec 08Market pulls back on stock over the past weekAfter last week's 16% share price decline to US$9.75, the stock is trading at a trailing P/E ratio of 19.5x, down from the previous P/E ratio of 23.2x. This compares to an average P/E of 51x in the Medical Equipment industry in the US. Total returns to shareholders over the past three years are 1,370%.Valuation Update With 7 Day Price Move • Dec 04Market pulls back on stock over the past weekAfter last week's 18% share price decline to US$10.00, the stock is trading at a trailing P/E ratio of 20x, down from the previous P/E ratio of 24.3x. This compares to an average P/E of 49x in the Medical Equipment industry in the US. Total returns to shareholders over the past three years are 1,503%.Valuation Update With 7 Day Price Move • Dec 02Market pulls back on stock over the past weekAfter last week's 24% share price decline to US$10.61, the stock is trading at a trailing P/E ratio of 21.2x, down from the previous P/E ratio of 27.8x. This compares to an average P/E of 49x in the Medical Equipment industry in the US. Total returns to shareholders over the past three years are 1,545%.분석 기사 • Dec 01How Should Investors React To Retractable Technologies' (NYSEMKT:RVP) CEO Pay?Thomas Shaw has been the CEO of Retractable Technologies, Inc. (NYSEMKT:RVP) since 1994, and this article will examine...Valuation Update With 7 Day Price Move • Nov 23Market bids up stock over the past weekAfter last week's 43% share price gain to US$12.01, the stock is trading at a trailing P/E ratio of 24x, up from the previous P/E ratio of 16.8x. This compares to an average P/E of 49x in the Medical Equipment industry in the US. Total returns to shareholders over the past three years are 1,747%.Is New 90 Day High Low • Nov 18New 90-day high: US$10.07The company is up 31% from its price of US$7.67 on 20 August 2020. The American market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 9.0% over the same period.Reported Earnings • Nov 18Third quarter 2020 earnings released: EPS US$0.33The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2020 results: Revenue: US$27.1m (up 133% from 3Q 2019). Net income: US$11.0m (up US$10.2m from 3Q 2019). Profit margin: 41% (up from 7.3% in 3Q 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 128% per year but the company’s share price has increased by 149% per year, which means it is tracking significantly ahead of earnings growth.Valuation Update With 7 Day Price Move • Oct 22Market pulls back on stock over the past weekAfter last week's 16% share price decline to US$7.71, the stock is trading at a trailing P/E ratio of 40.2x, down from the previous P/E ratio of 47.9x. This compares to an average P/E of 51x in the Medical Equipment industry in the US. Total returns to shareholders over the past three years are 1,059%.매출 및 비용 세부 내역Retractable Technologies가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이NYSEAM:RVP 매출, 비용 및 순이익 (USD Millions)날짜매출순이익일반관리비연구개발비31 Mar 2637-720131 Dec 2538-1320130 Sep 2538-719130 Jun 2538-919131 Mar 2534-2319131 Dec 2433-1219130 Sep 2438-1619130 Jun 2438-1819131 Mar 2440-819131 Dec 2344-720130 Sep 2342-1128130 Jun 2355-228031 Mar 2361-228131 Dec 2295529130 Sep 221423022130 Jun 221553122131 Mar 221834523131 Dec 211885622130 Sep 211614720130 Jun 211525118131 Mar 211214414131 Dec 20822712130 Sep 20621612130 Jun 2047611131 Mar 2045311131 Dec 1942211130 Sep 1937010130 Jun 1936-110131 Mar 1934-211131 Dec 1833-211130 Sep 1835-312130 Jun 1835-312131 Mar 1835-313131 Dec 1734-413130 Sep 1732-513130 Jun 1731-513131 Mar 1731-513131 Dec 1630-413130 Sep 1629-112130 Jun 1630-112131 Mar 1629613131 Dec 1530613130 Sep 1532514130 Jun 15346141양질의 수익: RVP 은(는) 현재 수익성이 없습니다.이익 마진 증가: RVP는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: RVP은 수익성이 없으며 지난 5년 동안 손실이 연평균 70.3% 증가했습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 RVP의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: RVP은 수익성이 없어 지난 해 수익 성장률을 Medical Equipment 업계(14.8%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: RVP는 현재 수익성이 없으므로 자본 수익률이 음수(-8.97%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YHealthcare 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/26 12:25종가2026/05/22 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Retractable Technologies, Inc.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
Reported Earnings • May 18First quarter 2026 earnings released: US$0.14 loss per share (vs US$0.35 loss in 1Q 2025)First quarter 2026 results: US$0.14 loss per share (improved from US$0.35 loss in 1Q 2025). Revenue: US$7.18m (down 14% from 1Q 2025). Net loss: US$4.28m (loss narrowed 59% from 1Q 2025). Over the last 3 years on average, earnings per share has fallen by 20% per year whereas the company’s share price has fallen by 19% per year.
Reported Earnings • Mar 30Full year 2025 earnings released: US$0.43 loss per share (vs US$0.41 loss in FY 2024)Full year 2025 results: US$0.43 loss per share (further deteriorated from US$0.41 loss in FY 2024). Revenue: US$38.3m (up 16% from FY 2024). Net loss: US$12.8m (loss widened 5.6% from FY 2024). Over the last 3 years on average, earnings per share has fallen by 45% per year but the company’s share price has only fallen by 27% per year, which means it has not declined as severely as earnings.
Reported Earnings • Nov 16Third quarter 2025 earnings released: EPS: US$0.01 (vs US$0.066 loss in 3Q 2024)Third quarter 2025 results: EPS: US$0.01 (up from US$0.066 loss in 3Q 2024). Revenue: US$10.1m (down 2.5% from 3Q 2024). Net income: US$313.4k (up US$2.29m from 3Q 2024). Profit margin: 3.1% (up from net loss in 3Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 48 percentage points per year, which is a significant difference in performance.
Reported Earnings • Mar 30Full year 2024 earnings released: US$0.41 loss per share (vs US$0.24 loss in FY 2023)Full year 2024 results: US$0.41 loss per share (further deteriorated from US$0.24 loss in FY 2023). Revenue: US$33.0m (down 24% from FY 2023). Net loss: US$12.1m (loss widened 67% from FY 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 76 percentage points per year, which is a significant difference in performance.
Reported Earnings • Nov 17Third quarter 2024 earnings released: US$0.066 loss per share (vs US$0.14 loss in 3Q 2023)Third quarter 2024 results: US$0.066 loss per share (improved from US$0.14 loss in 3Q 2023). Revenue: US$10.3m (flat on 3Q 2023). Net loss: US$1.98m (loss narrowed 52% from 3Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 60 percentage points per year, which is a significant difference in performance.
Reported Earnings • Aug 16Second quarter 2024 earnings released: US$0.47 loss per share (vs US$0.13 loss in 2Q 2023)Second quarter 2024 results: US$0.47 loss per share (further deteriorated from US$0.13 loss in 2Q 2023). Revenue: US$6.03m (down 24% from 2Q 2023). Net loss: US$14.2m (loss widened 262% from 2Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 55 percentage points per year, which is a significant difference in performance.
Reported Earnings • May 18First quarter 2026 earnings released: US$0.14 loss per share (vs US$0.35 loss in 1Q 2025)First quarter 2026 results: US$0.14 loss per share (improved from US$0.35 loss in 1Q 2025). Revenue: US$7.18m (down 14% from 1Q 2025). Net loss: US$4.28m (loss narrowed 59% from 1Q 2025). Over the last 3 years on average, earnings per share has fallen by 20% per year whereas the company’s share price has fallen by 19% per year.
공시 • Mar 30Retractable Technologies, Inc., Annual General Meeting, May 08, 2026Retractable Technologies, Inc., Annual General Meeting, May 08, 2026.
Reported Earnings • Mar 30Full year 2025 earnings released: US$0.43 loss per share (vs US$0.41 loss in FY 2024)Full year 2025 results: US$0.43 loss per share (further deteriorated from US$0.41 loss in FY 2024). Revenue: US$38.3m (up 16% from FY 2024). Net loss: US$12.8m (loss widened 5.6% from FY 2024). Over the last 3 years on average, earnings per share has fallen by 45% per year but the company’s share price has only fallen by 27% per year, which means it has not declined as severely as earnings.
Reported Earnings • Nov 16Third quarter 2025 earnings released: EPS: US$0.01 (vs US$0.066 loss in 3Q 2024)Third quarter 2025 results: EPS: US$0.01 (up from US$0.066 loss in 3Q 2024). Revenue: US$10.1m (down 2.5% from 3Q 2024). Net income: US$313.4k (up US$2.29m from 3Q 2024). Profit margin: 3.1% (up from net loss in 3Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 48 percentage points per year, which is a significant difference in performance.
Board Change • Oct 23Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 5 highly experienced directors. VP, CFO, Principal Accounting Officer,Treasurer & Director John Fort was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
공시 • Jul 24Retractable Technologies, Inc. Announces Reduction in Manufacturing WorkforceRetractable Technologies, Inc. reported that it has reduced its workforce by approximately 12.4%. The reduction is expected to save an estimated $1.6 million in annual wages and benefits, or approximately 8.6% of total estimated workforce costs. The expected savings is offset by one-time separation payments of approximately $56,000 to the affected workers. The reduction targets the Company's manufacturing and manufacturing support positions as the Company continues to balance its domestic manufacturing presence against its reliance on imported products and associated tariffs from its Chinese contract manufacturers. While contract manufacturers in China have historically produced most of the products the Company sells, the material financial impact of tariffs on Chinese imports has caused the Company to ramp-up its domestic production activities, while working to minimize the financial impact of the change. To the extent possible, the Company will continue to import only those products which it cannot make domestically and rely on its Little Elm facility to produce the remainder of its products. The Company is unable to predict future U.S. trade policy, or the potential impact it may have on the Company's ability to import products from China or other countries.
Board Change • Jul 10Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 4 highly experienced directors. VP, CFO, Principal Accounting Officer,Treasurer & Director John Fort was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
공시 • Apr 11Retractable Technologies, Inc. Announces Reduction in WorkforceRetractable Technologies, Inc. reported that it has reduced its workforce by approximately 7%. The reduction is expected to save an estimated $1.6 million in annual wages and benefits, or approximately 7.8% of total estimated workforce costs. The expected savings is offset by one-time separation payments of approximately $300,000 to the affected workers. Approximately 72% of the targeted payroll reduction affects general and administrative functions, with the remainder coming from manufacturing or manufacturing support positions. The move comes as the Company continues to allocate more of its resources to increase its U.S. manufacturing capabilities and reduce reliance on products produced in China. While contract manufacturers in China have historically produced most of the products the Company sells, the material financial impact of tariffs on imports from China eliminates the Company’s ability to continue the practice. As a result, the Company will work to minimize its exposure to the tariffs and strategically import only those products which it cannot make domestically and rely on its Little Elm facility to produce the majority of its products. The Company is unable to predict future U.S. trade policy, or the potential impact it may have on the Company’s ability to import products from China or other countries.
공시 • Mar 31Retractable Technologies, Inc., Annual General Meeting, May 09, 2025Retractable Technologies, Inc., Annual General Meeting, May 09, 2025.
Reported Earnings • Mar 30Full year 2024 earnings released: US$0.41 loss per share (vs US$0.24 loss in FY 2023)Full year 2024 results: US$0.41 loss per share (further deteriorated from US$0.24 loss in FY 2023). Revenue: US$33.0m (down 24% from FY 2023). Net loss: US$12.1m (loss widened 67% from FY 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 76 percentage points per year, which is a significant difference in performance.
Reported Earnings • Nov 17Third quarter 2024 earnings released: US$0.066 loss per share (vs US$0.14 loss in 3Q 2023)Third quarter 2024 results: US$0.066 loss per share (improved from US$0.14 loss in 3Q 2023). Revenue: US$10.3m (flat on 3Q 2023). Net loss: US$1.98m (loss narrowed 52% from 3Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 60 percentage points per year, which is a significant difference in performance.
Reported Earnings • Aug 16Second quarter 2024 earnings released: US$0.47 loss per share (vs US$0.13 loss in 2Q 2023)Second quarter 2024 results: US$0.47 loss per share (further deteriorated from US$0.13 loss in 2Q 2023). Revenue: US$6.03m (down 24% from 2Q 2023). Net loss: US$14.2m (loss widened 262% from 2Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 55 percentage points per year, which is a significant difference in performance.
Reported Earnings • May 17First quarter 2024 earnings released: EPS: US$0.012 (vs US$0.031 in 1Q 2023)First quarter 2024 results: EPS: US$0.012 (down from US$0.031 in 1Q 2023). Revenue: US$7.60m (down 31% from 1Q 2023). Net income: US$371.8k (down 60% from 1Q 2023). Profit margin: 4.9% (down from 8.5% in 1Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 43 percentage points per year, which is a significant difference in performance.
Reported Earnings • Apr 01Full year 2023 earnings released: US$0.24 loss per share (vs US$0.15 profit in FY 2022)Full year 2023 results: US$0.24 loss per share (down from US$0.15 profit in FY 2022). Revenue: US$43.6m (down 54% from FY 2022). Net loss: US$7.24m (down 250% from profit in FY 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 23 percentage points per year, which is a significant difference in performance.
공시 • Mar 30Retractable Technologies, Inc., Annual General Meeting, May 10, 2024Retractable Technologies, Inc., Annual General Meeting, May 10, 2024, at 10:00 Central Standard Time. Agenda: To vote on the election of three Class 2 Directors; and to consider other matters.
Reported Earnings • Nov 17Third quarter 2023 earnings released: US$0.13 loss per share (vs US$0.16 profit in 3Q 2022)Third quarter 2023 results: US$0.13 loss per share (down from US$0.16 profit in 3Q 2022). Revenue: US$10.3m (down 55% from 3Q 2022). Net loss: US$4.00m (down 175% from profit in 3Q 2022). Over the last 3 years on average, earnings per share has fallen by 54% per year whereas the company’s share price has fallen by 55% per year.
Reported Earnings • Aug 15Second quarter 2023 earnings released: US$0.13 loss per share (vs US$0.11 loss in 2Q 2022)Second quarter 2023 results: US$0.13 loss per share (further deteriorated from US$0.11 loss in 2Q 2022). Revenue: US$7.97m (down 44% from 2Q 2022). Net loss: US$3.93m (loss widened 6.1% from 2Q 2022). Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has fallen by 47% per year, which means it is performing significantly worse than earnings.
Reported Earnings • May 17First quarter 2023 earnings released: EPS: US$0.031 (vs US$0.23 in 1Q 2022)First quarter 2023 results: EPS: US$0.031 (down from US$0.23 in 1Q 2022). Revenue: US$11.0m (down 75% from 1Q 2022). Net income: US$932.9k (down 88% from 1Q 2022). Profit margin: 8.5% (down from 17% in 1Q 2022). Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 37% per year, which means it is significantly lagging earnings.
Reported Earnings • Mar 31Full year 2022 earnings released: EPS: US$0.15 (vs US$1.65 in FY 2021)Full year 2022 results: EPS: US$0.15 (down from US$1.65 in FY 2021). Revenue: US$94.8m (down 50% from FY 2021). Net income: US$4.85m (down 91% from FY 2021). Profit margin: 5.1% (down from 30% in FY 2021). Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has only increased by 12% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • Dec 01Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to US$1.97, the stock trades at a trailing P/E ratio of 2.2x. Average trailing P/E is 33x in the Medical Equipment industry in the US. Total returns to shareholders of 38% over the past three years.
Reported Earnings • Nov 17Third quarter 2022 earnings released: EPS: US$0.16 (vs US$0.19 in 3Q 2021)Third quarter 2022 results: EPS: US$0.16 (down from US$0.19 in 3Q 2021). Revenue: US$23.1m (down 37% from 3Q 2021). Net income: US$5.33m (down 18% from 3Q 2021). Profit margin: 23% (up from 18% in 3Q 2021). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 57% per year but the company’s share price has only increased by 20% per year, which means it is significantly lagging earnings growth.
Board Change • Nov 17Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 4 highly experienced directors. VP, CFO, Principal Accounting Officer,Treasurer & Director John Fort was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Valuation Update With 7 Day Price Move • Nov 10Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to US$2.05, the stock trades at a trailing P/E ratio of 2.2x. Average trailing P/E is 32x in the Medical Equipment industry in the US. Total returns to shareholders of 55% over the past three years.
Valuation Update With 7 Day Price Move • Oct 19Investor sentiment improved over the past weekAfter last week's 18% share price gain to US$2.28, the stock trades at a trailing P/E ratio of 2.4x. Average trailing P/E is 32x in the Medical Equipment industry in the US. Total returns to shareholders of 81% over the past three years.
Valuation Update With 7 Day Price Move • Sep 19Investor sentiment deteriorated over the past weekAfter last week's 18% share price decline to US$2.01, the stock trades at a trailing P/E ratio of 2.1x. Average trailing P/E is 33x in the Medical Equipment industry in the US. Total returns to shareholders of 99% over the past three years.
Board Change • Sep 06Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 4 highly experienced directors. VP, CFO, Principal Accounting Officer,Treasurer & Director John Fort was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
공시 • Jun 26+ 1 more updateRetractable Technologies, Inc.(NYSEAM:RVP) dropped from Russell 2000 Dynamic IndexRetractable Technologies, Inc.(NYSEAM:RVP) dropped from Russell 2000 Dynamic Index
공시 • Jun 07Retractable Technologies, Inc. Reports Reduction in WorkforceRetractable Technologies, Inc. reported that it has reduced its workforce by approximately 16% as a result of the substantial completion of its facility expansion efforts and the completion of U.S. government orders to provide its products for COVID-19 vaccination efforts. The staff reduction primarily affects its production, operations and logistics departments. The reduction will result in an overall annualized savings of approximately $2.1 million dollars, or 13% in annual payroll expense, and separation costs are expected to be approximately $200 thousand. The company expects that it will be able to maintain its current level of domestic production after the headcount reduction, and have significantly enhanced domestic production capacity upon completion of the expansion efforts.
Board Change • Jun 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 4 highly experienced directors. VP, CFO, Principal Accounting Officer,Treasurer & Director John Fort was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Valuation Update With 7 Day Price Move • May 31Investor sentiment improved over the past weekAfter last week's 19% share price gain to US$4.63, the stock trades at a trailing P/E ratio of 3.4x. Average trailing P/E is 36x in the Medical Equipment industry in the US. Total returns to shareholders of 573% over the past three years.
Reported Earnings • May 17First quarter 2022 earnings: EPS and revenues miss analyst expectationsFirst quarter 2022 results: EPS: US$0.23 (down from US$0.53 in 1Q 2021). Revenue: US$44.7m (down 11% from 1Q 2021). Net income: US$7.56m (down 58% from 1Q 2021). Profit margin: 17% (down from 36% in 1Q 2021). The decrease in margin was primarily driven by higher expenses. Revenue missed analyst estimates by 13%. Earnings per share (EPS) also missed analyst estimates by 47%. Over the last 3 years on average, earnings per share has increased by 94% per year but the company’s share price has only increased by 77% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • May 11Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to US$3.63, the stock trades at a trailing P/E ratio of 2.2x. Average trailing P/E is 33x in the Medical Equipment industry in the US. Total returns to shareholders of 438% over the past three years.
Board Change • May 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 4 highly experienced directors. VP, CFO, Principal Accounting Officer,Treasurer & Director John Fort was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Valuation Update With 7 Day Price Move • Apr 22Investor sentiment deteriorated over the past weekAfter last week's 19% share price decline to US$3.64, the stock trades at a trailing P/E ratio of 2.2x. Average trailing P/E is 38x in the Medical Equipment industry in the US. Total returns to shareholders of 406% over the past three years.
Reported Earnings • Apr 02Full year 2021 earnings: EPS and revenues miss analyst expectationsFull year 2021 results: EPS: US$1.65 (up from US$0.80 in FY 2020). Revenue: US$188.4m (up 130% from FY 2020). Net income: US$55.8m (up 110% from FY 2020). Profit margin: 30% (down from 33% in FY 2020). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 13%. Earnings per share (EPS) also missed analyst estimates by 47%. Over the last 3 years on average, earnings per share has increased by 109% per year but the company’s share price has only increased by 88% per year, which means it is significantly lagging earnings growth.
공시 • Apr 01Retractable Technologies, Inc., Annual General Meeting, May 10, 2022Retractable Technologies, Inc., Annual General Meeting, May 10, 2022, at 10:00 Central Standard Time. Agenda: To consider the election of Three Class 2 Directors; and to consider an advisory vote to approve executive compensation.
Reported Earnings • Nov 17Third quarter 2021 earnings released: EPS US$0.19 (vs US$0.33 in 3Q 2020)The company reported a mediocre third quarter result with weaker earnings and profit margins, although revenues improved. Third quarter 2021 results: Revenue: US$36.4m (up 34% from 3Q 2020). Net income: US$6.46m (down 41% from 3Q 2020). Profit margin: 18% (down from 41% in 3Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 120% per year but the company’s share price has increased by 134% per year, which means it is tracking significantly ahead of earnings growth.
Valuation Update With 7 Day Price Move • Oct 05Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to US$10.03, the stock trades at a trailing P/E ratio of 6.6x. Average trailing P/E is 48x in the Medical Equipment industry in the US. Total returns to shareholders of 1,290% over the past three years.
Reported Earnings • Aug 18Second quarter 2021 earnings released: EPS US$0.31 (vs US$0.11 in 2Q 2020)The company reported a solid second quarter result with improved earnings and revenues, although profit margins were weaker. Second quarter 2021 results: Revenue: US$42.5m (up 267% from 2Q 2020). Net income: US$10.6m (up 195% from 2Q 2020). Profit margin: 25% (down from 31% in 2Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 132% per year but the company’s share price has increased by 148% per year, which means it is tracking significantly ahead of earnings growth.
공시 • Jun 28+ 2 more updatesRetractable Technologies, Inc.(NYSEAM:RVP) dropped from Russell 3000E Value IndexRetractable Technologies, Inc.(NYSEAM:RVP) dropped from Russell 3000E Value Index
Valuation Update With 7 Day Price Move • Jun 09Investor sentiment improved over the past weekAfter last week's 19% share price gain to US$12.02, the stock trades at a trailing P/E ratio of 9.1x. Average trailing P/E is 56x in the Medical Equipment industry in the US. Total returns to shareholders of 1,384% over the past three years.
공시 • Jun 08Retractable Technologies, Inc. (NYSEAM:RVP) announces an Equity Buyback for $10 million worth of its shares.Retractable Technologies, Inc. (NYSEAM:RVP) announces a share repurchase program. Under the program, the company will repurchase up to $10 million worth of common stock. The program is valid until June 18, 2022.
Reported Earnings • May 19First quarter 2021 earnings released: EPS US$0.53 (vs US$0.005 in 1Q 2020)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: US$50.1m (up 347% from 1Q 2020). Net income: US$17.9m (up US$17.7m from 1Q 2020). Profit margin: 36% (up from 1.3% in 1Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 138% per year but the company’s share price has only increased by 120% per year, which means it is significantly lagging earnings growth.
Recent Insider Transactions • Apr 24Independent Director recently sold US$50k worth of stockOn the 22nd of April, Walter Bigby sold around 5k shares on-market at roughly US$10.02 per share. In the last 3 months, they made an even bigger sale worth US$186k. Insiders have been net sellers, collectively disposing of US$5.1m more than they bought in the last 12 months.
Valuation Update With 7 Day Price Move • Apr 08Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to US$10.59, the stock trades at a trailing P/E ratio of 13.2x. Average trailing P/E is 50x in the Medical Equipment industry in the US. Total returns to shareholders of 1,090% over the past three years.
Reported Earnings • Apr 03Full year 2020 earnings released: EPS US$0.80 (vs US$0.075 in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: US$81.9m (up 96% from FY 2019). Net income: US$26.6m (up US$24.2m from FY 2019). Profit margin: 33% (up from 5.9% in FY 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 136% per year but the company’s share price has increased by 142% per year, which means it is tracking significantly ahead of earnings growth.
분석 기사 • Mar 16Is Retractable Technologies (NYSEMKT:RVP) Using Too Much Debt?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Valuation Update With 7 Day Price Move • Mar 13Investor sentiment improved over the past weekAfter last week's 15% share price gain to US$13.65, the stock is trading at a trailing P/E ratio of 27.3x, up from the previous P/E ratio of 23.7x. This compares to an average P/E of 50x in the Medical Equipment industry in the US. Total returns to shareholders over the past three years are 1,275%.
분석 기사 • Feb 26Do Insiders Own Lots Of Shares In Retractable Technologies, Inc. (NYSEMKT:RVP)?If you want to know who really controls Retractable Technologies, Inc. ( NYSEMKT:RVP ), then you'll have to look at the...
Valuation Update With 7 Day Price Move • Feb 24Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to US$16.07, the stock is trading at a trailing P/E ratio of 32.2x, down from the previous P/E ratio of 38.2x. This compares to an average P/E of 56x in the Medical Equipment industry in the US. Total returns to shareholders over the past three years are 1,637%.
Recent Insider Transactions Derivative • Feb 21Vice President of Sales Development notifies of intention to sell stockRussell Kuhlman intends to sell 13k shares in the next 90 days after lodging an Intent To Sell Form on the 19th of February. If the sale is conducted around the recent share price of US$17.04, it would amount to US$223k. Since March 2020, Russell's direct individual holding has decreased from 46.00k shares to 13.10k. Company insiders have collectively sold US$5.0m more than they bought, via options and on-market transactions in the last 12 months.
공시 • Feb 18Retractable Technologies, Inc. Wins Firm Fixed Price and Cost Reimbursement Contract and Purchase OrderRetractable Technologies, Inc. announced that on February 12, 2021, it was awarded a firm fixed price and cost reimbursement contract and purchase order by the Department of Health and Human Services to supply low dead space safety syringes. The base price for the contract and purchase order is $54,217,800 for the five-month base period of performance (February 15, 2021 to July 14, 2021). Such price includes both the fixed price for the products as well as cost reimbursement for freight. The terms of the contract allow for extensions at the option of the U.S. government for up to seven additional one-month periods. If all option periods are exercised, the value of the contract could increase by an additional $92,772,680, including the price of the products and freight reimbursement. For each period, the freight cost is estimated at approximately 25% of the overall price.
분석 기사 • Feb 08Retractable Technologies (NYSEMKT:RVP) Knows How To Allocate Capital EffectivelyTo find a multi-bagger stock, what are the underlying trends we should look for in a business? Firstly, we'll want to...
Recent Insider Transactions • Feb 05Independent Director recently sold US$186k worth of stockOn the 2nd of February, Walter Bigby sold around 10k shares on-market at roughly US$18.55 per share. In the last 3 months, there was an even bigger sale from another insider worth US$3.0m. Insiders have been net sellers, collectively disposing of US$5.0m more than they bought in the last 12 months.
Valuation Update With 7 Day Price Move • Jan 29Investor sentiment improved over the past weekAfter last week's 29% share price gain to US$16.17, the stock is trading at a trailing P/E ratio of 32.4x, up from the previous P/E ratio of 25.2x. This compares to an average P/E of 53x in the Medical Equipment industry in the US. Total returns to shareholders over the past three years are 2,087%.
Is New 90 Day High Low • Jan 27New 90-day high: US$15.69The company is up 116% from its price of US$7.27 on 28 October 2020. The American market is up 17% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 9.0% over the same period.
Recent Insider Transactions • Jan 22Founder recently sold US$3.0m worth of stockOn the 14th of January, Thomas Shaw sold around 210k shares on-market at roughly US$14.24 per share. This was the largest sale by an insider in the last 3 months. This was Thomas' only on-market trade for the last 12 months.
Valuation Update With 7 Day Price Move • Jan 20Investor sentiment improved over the past weekAfter last week's 22% share price gain to US$13.57, the stock is trading at a trailing P/E ratio of 27.2x, up from the previous P/E ratio of 22.3x. This compares to an average P/E of 54x in the Medical Equipment industry in the US. Total returns to shareholders over the past three years are 1,798%.
분석 기사 • Jan 12Here's Why I Think Retractable Technologies (NYSEMKT:RVP) Might Deserve Your Attention TodayFor beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
분석 기사 • Dec 28Here's Why We Don't Think Retractable Technologies's (NYSEMKT:RVP) Statutory Earnings Reflect Its Underlying Earnings PotentialStatistically speaking, it is less risky to invest in profitable companies than in unprofitable ones. Having said that...
Valuation Update With 7 Day Price Move • Dec 23Investor sentiment deteriorated over the past weekAfter last week's 23% share price decline to US$11.64, the stock is trading at a trailing P/E ratio of 23.3x, down from the previous P/E ratio of 30.1x. This compares to an average P/E of 51x in the Medical Equipment industry in the US. Total returns to shareholders over the past three years are 1,696%.
Is New 90 Day High Low • Dec 16New 90-day high: US$15.00The company is up 147% from its price of US$6.08 on 16 September 2020. The American market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 7.0% over the same period.
Valuation Update With 7 Day Price Move • Dec 15Investor sentiment improved over the past weekAfter last week's 31% share price gain to US$12.77, the stock is trading at a trailing P/E ratio of 25.6x, up from the previous P/E ratio of 19.5x. This compares to an average P/E of 49x in the Medical Equipment industry in the US. Total returns to shareholders over the past three years are 1,751%.
분석 기사 • Dec 14Does Retractable Technologies (NYSEMKT:RVP) Have A Healthy Balance Sheet?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Valuation Update With 7 Day Price Move • Dec 11Investor sentiment improved over the past weekAfter last week's 21% share price gain to US$12.09, the stock is trading at a trailing P/E ratio of 24.2x, up from the previous P/E ratio of 20x. This compares to an average P/E of 50x in the Medical Equipment industry in the US. Total returns to shareholders over the past three years are 1,540%.
Valuation Update With 7 Day Price Move • Dec 08Market pulls back on stock over the past weekAfter last week's 16% share price decline to US$9.75, the stock is trading at a trailing P/E ratio of 19.5x, down from the previous P/E ratio of 23.2x. This compares to an average P/E of 51x in the Medical Equipment industry in the US. Total returns to shareholders over the past three years are 1,370%.
Valuation Update With 7 Day Price Move • Dec 04Market pulls back on stock over the past weekAfter last week's 18% share price decline to US$10.00, the stock is trading at a trailing P/E ratio of 20x, down from the previous P/E ratio of 24.3x. This compares to an average P/E of 49x in the Medical Equipment industry in the US. Total returns to shareholders over the past three years are 1,503%.
Valuation Update With 7 Day Price Move • Dec 02Market pulls back on stock over the past weekAfter last week's 24% share price decline to US$10.61, the stock is trading at a trailing P/E ratio of 21.2x, down from the previous P/E ratio of 27.8x. This compares to an average P/E of 49x in the Medical Equipment industry in the US. Total returns to shareholders over the past three years are 1,545%.
분석 기사 • Dec 01How Should Investors React To Retractable Technologies' (NYSEMKT:RVP) CEO Pay?Thomas Shaw has been the CEO of Retractable Technologies, Inc. (NYSEMKT:RVP) since 1994, and this article will examine...
Valuation Update With 7 Day Price Move • Nov 23Market bids up stock over the past weekAfter last week's 43% share price gain to US$12.01, the stock is trading at a trailing P/E ratio of 24x, up from the previous P/E ratio of 16.8x. This compares to an average P/E of 49x in the Medical Equipment industry in the US. Total returns to shareholders over the past three years are 1,747%.
Is New 90 Day High Low • Nov 18New 90-day high: US$10.07The company is up 31% from its price of US$7.67 on 20 August 2020. The American market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 9.0% over the same period.
Reported Earnings • Nov 18Third quarter 2020 earnings released: EPS US$0.33The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2020 results: Revenue: US$27.1m (up 133% from 3Q 2019). Net income: US$11.0m (up US$10.2m from 3Q 2019). Profit margin: 41% (up from 7.3% in 3Q 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 128% per year but the company’s share price has increased by 149% per year, which means it is tracking significantly ahead of earnings growth.
Valuation Update With 7 Day Price Move • Oct 22Market pulls back on stock over the past weekAfter last week's 16% share price decline to US$7.71, the stock is trading at a trailing P/E ratio of 40.2x, down from the previous P/E ratio of 47.9x. This compares to an average P/E of 51x in the Medical Equipment industry in the US. Total returns to shareholders over the past three years are 1,059%.